BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 12665831)

  • 1. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 3. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 4. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 5. More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
    Rinaldi A
    EMBO Rep; 2006 Feb; 7(2):133-6. PubMed ID: 16452923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 7. India aims to become the main bioinformatics hub.
    Jayaraman KS; Louët S
    Nat Biotechnol; 2004 Aug; 22(8):933. PubMed ID: 15286632
    [No Abstract]   [Full Text] [Related]  

  • 8. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 9. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 10. China moves to reform biotech policies.
    Jia H
    Nat Biotechnol; 2004 Oct; 22(10):1197. PubMed ID: 15470442
    [No Abstract]   [Full Text] [Related]  

  • 11. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 12. Germany biotech gets second chance.
    Sheridan C
    Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
    [No Abstract]   [Full Text] [Related]  

  • 13. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 14. Realizing potential: the state of Asian bioentrepreneurship.
    Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
    [No Abstract]   [Full Text] [Related]  

  • 15. Malaysia tiptoes on the heels of Asian neighbors.
    Fuyuno I
    Nat Biotechnol; 2005 Aug; 23(8):908-9. PubMed ID: 16082349
    [No Abstract]   [Full Text] [Related]  

  • 16. Germany reattempts to spark innovation.
    Habeck M
    Nat Biotechnol; 2004 Mar; 22(3):257-8. PubMed ID: 14990939
    [No Abstract]   [Full Text] [Related]  

  • 17. France to focus on a few biotech clusters.
    Balcon E
    Nat Biotechnol; 2004 Sep; 22(9):1063-4. PubMed ID: 15340457
    [No Abstract]   [Full Text] [Related]  

  • 18. Special: biotech in Russia.
    Rabinovich M; Burghardt N; Gorzka G; Kudryashev M; Leonov A; Konov A
    Biotechnol J; 2007 Jul; 2(7):775-89. PubMed ID: 17615597
    [No Abstract]   [Full Text] [Related]  

  • 19. Japanese council urges reform of funding system.
    Triendl R
    Nat Biotechnol; 2002 Dec; 20(12):1176-8. PubMed ID: 12454656
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotech firms jump on SARS bandwagon.
    Basu P
    Nat Biotechnol; 2003 Jul; 21(7):720. PubMed ID: 12833076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.